Статья
ГЕНЕТИЧЕСКИЙ ПРОФИЛЬ И СЕКРЕТОМ АДИПОЦИТОВ ВИСЦЕРАЛЬНОЙ И ПОДКОЖНОЙ ЖИРОВОЙ ТКАНИ У ПАЦИЕНТОВ С СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ
Жировая ткань представляет особый интерес в контексте ее ключевой роли в патогенезе сердечно-сосудистых заболеваний, дисфункции эндотелия и миокарда, гипертонии, атеросклероза и ряда других патологических состояний. На настоящий момент накоплено достаточное количество сведений о секреторной функции адипоцитов, что ведет к признанию роли жировой ткани в регуляции функционирования сердечно-сосудистой системы. Изучения молекулярно-генетических основ функционирования жировой ткани может помочь более глубокому пониманию этиопатогенетических механизмов сердечно-сосудистых заболеваний и разработать эффективную стратегию их профилактики и контроля. В данном обзоре проанализирована информация об особенностях профиля адипокинов и цитокинов, секретируемых различными типами жировой ткани (подкожная, эпикардиальная, периваскулярная), а также об изменении экспрессии ряда ключевых генов в адипоцитах, полученных из различных жировых депо, у пациентов с сердечно-сосудистыми заболеваниями.
1. Gualillo O., Gonzalez-Juanatey J.R., Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med. 2007; 17(8): 275-283. doi:10.1016/j.tcm.2007.09.005.
2. Самородская И.В., Кондрикова Н.В. Сердечно-сосудистые заболевания и ожирение. Возможности бариатрической хирургии. Комплексные проблемы сердечно-сосудистых заболеваний. 2015; 3: 53-60. doi:10.17802/2306-1278-2015-3-53-60. Samorodskaya I.V., Kondrikova N.V. Cardiovascular diseases and obesity. Possibilities of bariatric surgery. Complex Issues of Cardiovascular Diseases. 2015; 3: 53-60.. doi:10.17802/2306-1278-2015-3-53-60.
3. Бородкина Д.А., Груздева О.В., Квиткова Л.В., Барбараш О.Л. Можно ли назвать висцеральное ожирение ключевым факторам парадокса ожирения? Проблемы эндокринологии. 2016; 6: 33-39. doi:10.14341/probl2016626?-?. Borodkina D.A., Gruzdeva O.V., Kvitkova L.V., Barbarash O.L. Is visceral obesity the cause of obesity paradox? Problems of endocrinology. 2016; 6: 33-39.. doi:10.14341/probl2016626?-?.
4. Wronkowitz N., Romacho T., Sell H., Eckel G. Adipose Tissue Dysfunction and Inflammation in Cardiovascular Disease. Front Horm Res. 2014; 43: 79-92. doi:10.1159/000360560.
5. Trayhurn P., Drevon C.A., Eckel J. Secreted proteins from adipose tissue and skeletal muscle – adipokines, myokines and adipose/muscle crosstalk. Arch Physiol Biochem. 2011; 117(2): 47-56. doi:10.3109/13813455.2010.535835.
6. Lehr S., Hartwig S., Lamers D., Famulla S., Muller S., Hanisch F.G. et al. Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics. 2012; 11(1): M111.010504. doi:10.1074/mcp.M111.010504.
7. Yim J., Rabkin S.W. Differences in Gene Expression and Gene Associations in Epicardial Fat Compared to Subcutaneous Fat. Horm Metab Res. 2017; 49(5): 327-337. doi:10.1055/s-0042-119202.
8. Bosello O., Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000; 1(1): 47-56.
9. Gaborit B., Venteclef N., Ancel P., Pelloux V., Gariboldi V., Leprince P. et al. Human epicardial adipose tissue has a specific transcriptomic signature depending on its anatomical peri-atrial, periventricular, or peri-coronary location. Cardiovasc Res. 2015; 108(1): 62-73. doi:10.1093/cvr/cvv208.
10. Barbarash O., Gruzdeva O., Uchasova E., Dyleva Y., Belik E., Akbasheva O. et al. The role of adipose tissue and adipokines in the manifestation of type 2 diabetes in the long-term period following myocardial infarction. Diabetol Metab Syndr. 2016; 8: 24. doi:10.1186/s13098-016-0136-6.
11. Романцова Т.И., Овсянникова А.В. Периваскулярная жировая ткань: роль в патогенезе ожирения, сахарного диабета 2 типа и сердечно-сосудистой патологии. Ожирение и метаболизм. 2015; 12(4): 5-13. doi:10.14341/OMET201545-13. Romantsova T. I., Ovsiannikova A.V. Perivascular adipose tissue: role in the pathogenesis of obesity, type 2 diabetes mellitus and cardiovascular pathology. Obesity and metabolism. 2015; 12(4): 5-13.. doi:10.14341/OMET201545-13.
12. Груздева О.В., Акбашева О.Е., Дылева Ю.А., Антонова Л.В., Матвеева В.Г. и соавт. Адипокиновый и цитокиновый профили эпикардиальной и подкожной жировой ткани у пациентов с ишемической болезнью сердца. Бюллетень экспериментальной биологии и медицины. 2017; 163(5): 560-563. Gruzdeva O.V., Akbasheva O.E., Dyleva Y.A., Antonova L.V., Matveeva V.G. et al. Adipokinovyj i citokinovyj profili ehpikardial’noj i podkozhnoj zhirovoj tkani u pacientov s ishemicheskoj bolezn’yu serdca. Byulleten’ ehksperimental’noj biologii i mediciny. 2017; 163(5): 560-563..
13. Wu F.G., Wu C.C., Kuo P.L., Wu M.T. Differential impacts of cardiac andabdominal ectopic fat deposits on cardiometabolic risk stratification. BMC Cardiovascular Disorders. 2016; 6: 20. doi:10.1186/s12872-016-0195-5..
14. Venteclef N., Guglielmi V., Balse E., Gaborit B., Cotillard A., Atassi F. et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines. Eur. Heart J. 2015; 36(13): 795-805a. doi: 10.1093/eurheartj/eht099.
15. Sell H., Habich C., Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012; 8(12): 709-716. doi:10.1038/nrendo.2012.114.
16. Greulich S., Chen W.J., Maxhera B., Rijzewijk L.J., van der Meer R.W., Jonker J.T. et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One. 2013; 8(3): e59697. doi:10.1371/journal.pone.0059697.
17. Taube A., Schlich R., Sell H., Eckardt K., Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012; 302(11): H2148-65. doi:10.1152/ajpheart.00907.2011.
18. Rothenbacher D., Brenner H., März W., Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J. 2005; 26(16): 1640-1646.
19. Bambacea C., Telescab M., Zoicoa E., Sepea A., Oliosoa D., Rossia A. et al. Adiponectin gene expression and adipocyte diameter: a comparison between epicardial and subcutaneous adipose tissue in men. Cardiovascular Pathology. 2011; 20(5): e153-156. doi:10.1016/j.carpath.2010.07.005.
20. Bambace C., Sepe A., Zoico E., Telesca M., Olioso D., Venturi S. et al. Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels. 2014; 29(1): 42-48. doi:10.1007/s00380-012-0315-9.
21. Gormez S., Demirkan A., Atalar F., Caynak B., Erdim R., Sozer V. et al. Adipose tissue gene expression of adiponectin, tumor necrosis factoralpha and leptin in metabolic syndrome patients with coronary artery disease. Intern Med. 2011; 50(8): 805-910.
22. Spener R.F., Breda J.R., Pires A.C., Pinhal M.A., Souto R.P. Adiponectin expression in epicardial adipose tissue after percutaneous coronary intervention with bare-metal stent. Rev Bras Cir Cardiovasc. 2011; 26(3): 427-432.
23. Teijeira-Fernandez E., Eiras S., GrigorianShamagian L., Fernandez A., Adrio B., GonzalezJuanatey J.R. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens. 2008; 22(12): 856-863. doi:10.1038/jhh.2008.75.
24. Eiras S., Teijeira-Fernandez E., Shamagian L.G., Fernandez A.L., Vazquez-Boquete A., Gonzalez-Juanatey J.R. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine. 2008; 43(2): 174-180. doi:10.1016/j.cyto.2008.05.006.
25. Iacobellis G., Pistilli D., Gucciardo M., Leonetti F., Miraldi F., Brancaccio G. et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005; 29(6): 251-255.
26. Bettencourt N., Toschke A.M., Leite D., Rocha J., Carvalho M., Sampaio F. et al. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol. 2011; 158(1): 26-32. doi:10.1016/j.ijcard.2010.12.085.
27. Shibasaki I., Nishikimi T., Mochizuki Y., Yamada Y., Yoshitatsu M., Inoue Y. et al. Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease. Regul Pept. 2010; 165(2-3): 210-217. doi:10.1016/j.regpep.2010.07.169.
28. Iacobellis G., Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005; 90(11): 6300-6302.
29. Mahabadi A.A., Lehmann N., Kalsch H., Robens T., Bauer M., Dykun I. et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: Results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging. 2014; 7(9): 909-916.
30. Fernández-Trasancos Á., Guerola-Segura R., Paradela-Dobarro B., Álvarez E., García-Acuña J.M., Fernández Á.L. et al. Glucose and Inflammatory Cells Decrease Adiponectin in Epicardial Adipose Tissue Cells: Paracrine Consequences on Vascular Endothelium. J. Cell. Physiol. 2016; 231(5): 1015-1023. doi:10.1002/jcp.25189.
31. Elie A.G., Jensen P.S., Nissen K.D., Geraets I.M., Xu A., Song E. et al. Adipokine Imbalance in the Pericardial Cavity of Cardiac and Vascular Disease Patients. PLoS One. 2016; 11(5): e0154693. doi:10.1371/journal.pone.0154693.
32. Harada K., Amano T., Kataoka T., Takeshita M., Harada K., Kunimura A. et al. Impact of abdominal and epicardial fat on the association between plasma adipocytokine levels and coronary atherosclerosis in nonobese patients. Atherosclerosis. 2014; 237(2): 671-676. doi:10.1016/j.atherosclerosis.2014.10.014.
33. Iglesias M.J., Eiras S., Piñeiro R., LópezOtero D., Gallego R., Fernández A.L. et al. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Rev española Cardiol. 2006; 59(12): 1252-1260.
34. Kremen J., Dolinkova M., Krajickova J., Blaha J., Anderlova K., Lacinova Z. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab. 2006; 91(11): 4620-4627.
35. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M. et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60(7): 1917-1925. doi:10.2337/db10-1707.
36. Sell H., Bluher M., Kloting N., Schlich R., Willems M., Ruppe F. et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013; 36(12): 4083-4090. doi:10.2337/dc13-0496.
37. Zhong J., Rao X., Rajagopalan S: An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013; 226(2): 305-314. doi:10.1016/j.atherosclerosis.2012.09.012.
38. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011; 55(1-3): 10-16. doi:10.1016/j.vph.2011.05.001.
39. Bonnet F., Scheen A.J. Impact of glucoselowering therapies on risk of stroke in type 2 diabetes. Diabetes Metab. 2017; pii: S1262-3636(17)30075-7. doi:10.1016/j.diabet.2017.04.004.
40. LeBras M.H., Barry A.R., Koshman S.L. Cardiovascular safety outcomes of new antidiabetic therapies. Am J Health Syst Pharm. 2017; pii: e285. doi:10.2146/ajhp160279.
41. Berti L., Hartwig S., Irmler M., Rädle B., Siegel-Axel D., Beckers J. et al. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem. 2016; 122(5): 281-288.
42. Wang Y. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol. 2012; 165(3): 603-621. doi:10.1111/j.1476-5381.2011.01528.x.
43. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307(5708): 426-430.
44. Romacho T., Sanchez-Ferrer C.F., Peiro C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm. 2013; 2013: 946427. doi:10.1155/2013/946427.
45. Sommer G., Garten A., Petzold S., BeckSickinger A.G., Bluher M., Stumvoll M. et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond). 2008; 115(1): 13-23. doi:10.1042/CS20070226.
46. Filippatos T.D., Randeva H.S., Derdemezis C.S., Elisaf M.S., Mikhailidis D.P. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol. 2010; 8(1): 12-28.
47. Spiroglou S.G., Kostopoulos C.G., Varakis J.N., Papadaki H.H. Adipokines in Periaortic and Epicardial Adipose Tissue: Differential Expression and Relation to Atherosclerosis. Journal of Atherosclerosis and Thrombosis. 2010; 17(2): 115-130. doi:10.5551/jat.1735.
48. Tan B.K., Adya R., Randeva H.S. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010; 20(5): 143-148. doi:10.1016/j.tcm.2010.12.002.
49. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011; 34(3): 307-310.
50. Moreno-Navarrete J.M., Ortega F., Castro A., Sabater M., Ricart W., Fernandez-Real J.M. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring). 2011; 19(8): 1552-1559. doi:10.1038/oby.2010.351.
51. Barnes G., Japp A.G., Newby D.E. Translational promise of the apelin-APJ system. Heart. 2010; 96(13): 1011-1016. doi:10.1136/hrt.2009.191122.
52. Averill M.M., Barnhart S., Becker L., Li X., Heinecke J.W., Leboeuf R.C. et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011; 123(11): 1216-1226. doi:10.1161/CIRCULATIONAHA.110.985523.
53. Zhao F., Hoechst B., Duffy A., Gamrekelashvili J., Fioravanti S., Manns M.P. et al. S100A9 a new marker for monocytic human myeloid derived suppressor cells. Immunology. 2012; 136(2): 176-183. doi:10.1111/j.1365-2567.2012.03566.x.
54. Agra R.M., Fernández-Trasancos Á., Sierra J., González-Juanatey J.R., Eiras S. Differential association of S100A9, an inflammatory marker, and p53, a cell cycle marker, expression with epicardial adipocyte size in patients with cardiovascular disease. Inflammation. 2014; 37(5): 1504-1512. doi:10.1007/s10753-014-9876-3.
55. Agra R.M., Teijeira-Fernández E., Pascual-Figal D., Sánchez-Más J., Fernández-Trasancos A., González-Juanatey J.R. et al. Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients. Eur J Clin Invest. 2014; 44(1): 29-37. doi:10.1111/eci.12186. Epub 2013 Nov 14.
56. Zhao R., Xiang N., Domann F.E., Zhong W. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res. 2006; 66(4): 2296-304.
57. Molchadsky A., Shats I., Goldfinger N., Pevsner-Fischer M., Olson M., Rinon A. et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS ONE. 2008; 3(11): e3707. doi:10.1371/journal.pone.0003707.
58. Bazuine M., Stenkula K.G., Cam M., Arroyo M., Cushman S.W. Guardian of corpulence: a hypothesis on p53 signaling in the fat cell. Clin Lipidol. 2009; 4(2): 231-243.
59. Dutour A., Achard V., Sell H., Naour N., Collart F., Gaborit B. et al. Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease. J Clin Endocrinol Metab. 2010; 95(2): 963-967. doi:10.1210/jc.2009-1222.
60. Sacks H.S, Fain J.N., Cheema P., Bahouth S.W., Garrett E., Wolf R.Y. et al. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord. 2011; 9(6): 433-439. doi:10.1089/met.2011.0024.
61. Bilgic Gazioglu S., Akan G., Atalar F., Erten G. PAI-1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients. Int J Clin Exp Pathol. 2015; 8(12): 15919-15925.
62. Chatterjee T.K., Aronow B.J., Tong W.S., Manka D., Tang Y., Bogdanov V.Y. et al. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasis. Physiol Genomics. 2013; 45(16): 697-709. doi:10.1152/physiolgenomics.00042.2013.
63. Guauque-Olarte S., Gaudreault N., Piche M.E., Fournier D., Mauriege P., Mathieu P. et al. The transcriptome of human epicardial, mediastinal and subcutaneous adipose tissues in men with coronary artery disease. PLoS One. 2011; 6(5): e19908. doi:10.1371/journal.pone.0019908.